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Abstract
Background: Diencephalic Syndrome is a rare clinical condition of failure to thrive despite a normal caloric intake,
hyperalertness, hyperkinesis, and euphoria usually associated with low-grade hypothalamic astrocytomas.
Case presentation: We reported an unusual case of diencephalic cachexia due to hypothalamic anaplastic
astrocytoma (WHO-grade III). Baseline endocrine function evaluation was performed in this patient before surgery.
After histological diagnosis, he enrolled to a chemotherapy program with sequential high-dose chemotherapy
followed by hematopoietic stem cell rescue. The last MRI evaluation showed a good response. The patient is still
alive with good visual function 21 months after starting chemotherapy.
Conclusions: Diencephalic cachexia can rarely be due to high-grade hypothalamic astrocytoma. We suggest that a
nutritional support with chemotherapy given to high doses without radiotherapy could be an effective strategy for
treatment of a poor-prognosis disease.
Background
Failure to thrive (FTT) is an important and relatively fre-
quent problem in infancy. In developed countries, in pres-
ence of a FTT in childhood, an uncommon disease must
be suspected if dietary and behavioral interventions have
been unsuccessful. An insufficient caloric intake, inad-
equate caloric absorption, or increased energy requirements
may cause a state of malnutrition and all the diagnostic ef-
forts adopted should be aimed to distinguish the source [1].
Common pediatric conditions associated with FTT are
gastro-esophageal reflux, Crohn’s disease, celiac disease,
cystic fibrosis, psychiatric disorder like nervous anorexia
and other chronic illness (neurological, cardiac, nephro-
logical, rheumatological, oncological, pulmonary, immuno-
logical diseases and chronic infections). Although FTT of
in pediatric age is frequent, the organic causes are rare [2].
Diencephalic Syndrome (DS), also known as Russell
syndrome or diencephalic cachexia, is a rare condition
associated with a hypothalamic/chiasmatic tumor [3]. The
DS is a rare disorder but potentially lethal, therefore its
rapid diagnosis and treatment are critical for patient’s life.
Tumors related with DS are usually pilocytic (WHO-
grade I) or pilomyxoid (WHO-grade II) astrocytomas in
young children. Clinical features of DS are loss of weight
leading to severe emaciation despite a normal caloric in-
take, hyperalertness, hyperkinesis, and euphoria. Growth
rate usually remains linear. Since the first report of DS,
additional symptoms such as nystagmus, hydrocephalus
and vomiting have been reported to be possible manifes-
tations of the syndrome [4, 5].
Treatment of DS is strictly related to treatment of the
hypothalamic lesion: it has been shown that DS clinical
signs and symptoms regress when the tumor is surgically
removed or reduced by non-surgical therapy. Since
complete resection of hypothalamic-chiasmatic lesions is
often difficult, partial resection is followed by chemo-
therapy and/or radiotherapy, which may represent the
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only treatment when the mass is not resectable [6].
However, being young children, radiotherapy is not the
first choice of treatment. Various chemotherapy regi-
mens were assessed for arresting tumor growth in this
type of tumors. As long as the DS signs and symptoms
are present, patients need nutritional support to avoid
consequences of emaciation and cachexia.
The experience reported here suggests that high doses
chemotherapy with autologous stem cell transplantation
could be effective in achieving a lasting progression free
survival in DS patients associated to a hypothalamic high-
grade astrocytoma. The significance of our experience
stems from the fact that there are only clinical studies for
the treatment of low-grade gliomas in DS patients.
Case presentation
In February 2013, a five-month-old infant was admitted to
our hospital for weight loss (<3rd percentile) on the advice
of his pediatrician (Fig. 1). He was a full-term newborn with
no history of inadequate nutrition or gastrointestinal symp-
toms. The physical examination revealed pallid and dry
skin, lack of subcutaneous fat, thin and triangular face,
sunken anterior fontanelle, muscle wasting, restlessness,
motor hyperactivity, euphoria, nystagmus and convergent
strabismus of the left eye. Blood tests, analysis of stool sam-
ples and abdominal ultrasound excluded the malabsorption
as cause of his state of malnutrition. A cranial TC scan was
performed and revealed the presence of a lesion at the
suprasellar region. The Gd-enhanced MRI of brain, subse-
quently required, showed contrast uptake in the perimedul-
lary cisterns (Fig. 2,a-b). The spinal MRI showed absence of
leptomeningeal metastases. The patient underwent to a bi-
opsy with sub-frontal access and his postoperative course
was without complications. The histopathological examin-
ation revealed a proliferation of astrocytes with nuclear
atypia and mitotic activity (6X10 HPF) without vascular
proliferation or necrosis. By immunohistochemical
staining the neoplastic cells were GFAP positive and
Synaptophysin and p53 negative. The proliferation
index determined estimating the percentage of the Ki-
67 positive neoplastic cells on the total of the tumor
cells was about 18 %. We did not identify the V600E
and KIAA1549 BRAF fusion gene mutations [7]. Fur-
thermore, we did not evidence the presence of H3F3A
K27M mutation [8]. The histopathological diagnosis
was anaplastic astrocytoma (WHO-grade III). Diagnosis
was confirmed by the review of the CNS national panel
of pathologists. Therefore, he began a high dose chemo-
therapy program according to Italian schedule for Infant
CNS tumors that included methotrexate, etoposide, cyclo-
phosphamide, vincristine and carboplatin, two cycles of
high-dose chemotherapy (thiotepa) and reinfusion of au-
tologous stem cells [9]. The patient described in this study
needed nutritional support and was monitored by the
nutritional point of view during the treatment and the
subsequent follow up. Parenteral nutrition was promptly
started. Unfortunately the patient underwent several com-
plications that hindered his weight recovery. He developed
a syndrome of inappropriate secretion of antidiuretic
hormone following the first two chemotherapy cycles.
After only 1 month of parenteral nutrition, a central
venous catheter infection by Staphylococcus hominis
and Staphylococcus epidermidis occurred. Therefore,
the parenteral nutrition was interrupted and replaced
with enteral nutrition by nasogastric tube.
Five months after diagnosis, the MRI scans showed a
lesion of reduced volume (partial response according to
RANO criteria) [10] (Fig. 2,c-d). After recovery from the
complications, weight started to increase until to a satis-
factory level (Fig. 1). Our young patient was still being
actively followed up at the time of this report. He
remains alive with residual disease 27 months after start-
ing chemotherapy (stable disease according to RANO
criteria) [10] (Fig. 2,e-f ).
Fig. 1 Photomicrographs of the lesion: astrocytes with nuclear atipia and mitosis (arrows) (a: hematoxylin and eosin, 40X) and high proliferation
index (b, Ki-67 mmunocoloration, 10X). The surgical sample was routinely fixed in neutral buffered formol and embedded in paraffin. One 5 μm
thick histological section obtained from each paraffin block was stained with hematoxylin and eosin. Further sections of the most representative
paraffin block were used for immunohistochemistry and molecular analysis. Immunohistochemical studies were performed using the standard
streptavidin-biotin technique and commercially available antibodies (Glial Fibrillary Acidic Protein, GFAP; p53 protein; Synaptophysin, SP; Ki-67).
BRAF and H3F3 genes were analyzed as previously described [7, 8]
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Conclusions
FTT can be defined as a condition characterized by a
poor weight gain or severe weight loss. It may result
from various disorders as unfavorable environments,
psychological factors, or organic disease. The core ques-
tion in the presence of suspected FTT is the cause of
malnutrition. Diagnostic efforts should be directed to-
ward determining whether the problem is secondary to
inadequate intake, insufficient absorption, or excessive
calorie requirement. Despite its clinical variability, FTT
remains the most common symptom of DS at the
diagnosis, and the main cause bringing the patient to
medical attention, while length/height usually remains
unaffected [4, 5, 11, 12]. Clinical features of emaciation,
that may raise the suspicion of DS associated with CNS
tumors, are weight loss, marked lack of subcutaneous
fat and generalized lipodistrophy, without evidence of
malabsorption, and evidence of psychic disturbance.
Some of the most common symptoms at onset include
visual acuity loss, visual field deficits, strabismus, nys-
tagmus, proptosis and hypothalamic syndrome due to
the hormonal dysfunction [4, 13–15].
It is not known whether weight loss in DS patients is
due to increased energy consumption, inadequate ab-
sorption, or both. Neoplastic disease may lead to key
changes of intermediary metabolism and feeding behav-
ior, resulting in loss of fat reserves and lean body mass,
i.e. the so-called cancer cachexia [16]. Supplemental
feeding without any other intervention is not sufficient
to reverse the syndrome, because emaciation and tumor
growth go on. The mean survival of no-treated DS pa-
tients is usually less than 12 months [17]. Yet, effective
therapy is hampered by the tumor location preventing
its complete resection, and by significant neurocognitive
and endocrinological sequelae associated with potentially
curative radiotherapy. The role of surgery in treatment of
optic chiasm lesions in DS patients is not clear. Surgery of
hypothalamic area carries with it the risk of immediate,
adverse neurologic and endocrinologic sequelae. The ex-
tensive surgical resection may result in a transient disease
control. A recent report showed improvement of cach-
exia after partial surgery following failure of chemo-
therapy [7]. The positive impact of gross total removal
on prognosis has been reported extensively in the lit-
erature. The Baby POG I study showed the degree of
surgical resection had poor influence on overall survival
as well as underlined in the French study on children
under 5 years of age (BBSFOP) [18, 19].
In contrast to other LGG therapies, our recent experi-
ence, showed that lower doses of cisplatin (25 mg/m2/
day) and etoposide (100 mg/m2/day) is probably one of
the most active regimens with reduced neurotoxicity
and myelotoxicity to treat children with DS related to
low-grade optic-hypothalamic glioma [20].
The outcome for children with high-grade astrocyto-
mas remains dismal despite aggressive surgical resection
and radiotherapy followed by adjuvant chemotherapy.
In an effort to improve the outcome for this group of
children, clinicians have studied the role of high-dose
marrow-ablative chemotherapy followed by autologous
hematopoietic cell rescue.
Garrè et al. showed data on a small series of centrally
reviewed malignant glioma in children younger than 3 years
at diagnosis who were treated, in six instances, with a
schedule of sequential high-dose chemotherapy utilizing
high-dose methotrexate, etoposide, cyclophosphamide and
carboplatin, followed by two courses with carboplatin/eto-
poside and thiotepa/melphalan at myeloablative doses and
Fig. 2 Serial MRI scans showing response to high doses chemotherapy in a five-month-old infant with hypothalamic anaplastic astrocytoma. Axial
and coronal Gd-enhanced T1-weighted MR scans: immediately post-biopsy image of the hypothalamic lesion (a-b); c post-chemotherapy MRI
scans demonstrating a partial response (c-d); MRI scans showing a stable disease 27 months from diagnosis (e-f)
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hematopoietic stem cell rescue. Focal radiotherapy was
given only in case of progressive and/or residual disease at
the end of chemotherapy [7].
We reported a rare case of diencephalic syndrome
due to hypothalamic anaplastic astrocytoma (WHO-
grade III). He enrolled to a chemotherapy program with
sequential high-dose chemotherapy followed by two
courses with thiotepa at myeloablative doses and au-
tologous hematopoietic stem cell transplantation. The
patient is still alive with stable disease and good visual
function 27 months after starting chemotherapy.
Many investigators have evaluated the endocrinological
abnormalities that might play a role in the pathogenesis of
DS. It has been reported that either GH levels have been
elevated or the regulation of GH secretion has been al-
tered. Especially, partial GH resistance in DS patients has
been observed [12]. Additional studies of hypothalamic-
pituitary factors involved in appetite regulation and me-
tabolism may clarify DS pathogenesis. It was hypothesized
that cytokines as IL-1, IL-6, IFN-γ, TNF-α, brain-derived
neurotrophic factor, MIC-1 may be involved in the cach-
exia process, in the imbalance which favors catabolism
over anabolism, and in the neurologic and neuropsychi-
atric manifestations of the disease. Tumor-derived mol-
ecules, peptides/neuropeptides, neurotransmitters and
hormones as leptin and GH-relin may interact with cy-
tokines in the generation/development of the cachexia
process [21]. Although these biochemical changes have
been described as pathological mechanisms of the can-
cer cachexia, unfortunately biochemical causes of the
DS remain unknown.
DS patients need an adequate nutritional support,
which should be established as soon as possible. The
oral route is the first choice. However, in several cases,
enteral or parenteral nutrition may provide to children
unable to feed the nutrients necessary to ensure proper
growth, to correct or prevent malnutrition [22].
The choice between different types of artificial feeding
should be done based on the clinical conditions. In
particular, enteral administration of nutrients through
the digestive system-wide probe is indicated in patients
with oral nutrition not sufficient to maintain an ad-
equate nutritional status. To this purpose, gastrostomy
is widely applied for its safe, direct access to the stomach
through the abdominal wall. Parenteral administration
should be considered only as a second choice when en-
teral intervention has failed.
In this report we considered an anomalous clinical case
of diencephalic cachexia due to an hypothalamic anaplas-
tic astrocytoma. The winning strategy in the treatment of
children with DS should take into account the nutritional
support with chemotherapy given from standard to high
doses, depending on the grade of the tumor. We suggest
that a prompt diagnosis and a histological revision after
diagnosis of hypothalamic tumors are mandatory for an
accurate treatment of a poor-prognosis disease.
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